YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
A study showed Novavax's COVID-19 vaccine had a 100% efficacy against the original strain of the coronavirus and 93% efficacy against more worrisome variants that have subsequently appeared.
The study, which involved nearly 30,000 volunteers in the United States and Mexico, also showed it was safe for users. Like other COVID-19 vaccines, it caused headaches, chills and muscle aches after injection, but few of these side effects were considered serious or severe.
The company says it intends to file for authorization from regulators in the U.S., Europe and the United Kingdom later this summer. Novavax says it will be able to deliver 100 million doses per month by the end of September and 150 million doses per month by the end of the year.
Read more from NPR.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Eric Schmitt introduces Modern Skies Act
Caterpillar to acquire John Fabick Tractor Co.
Springfield airport to cut the ribbon on $35M in construction projects
Legacy Bank accused in lawsuit of failing to protect customers in data breach